Bluebird Ventures
Bluebird Ventures is an early-stage life sciences venture firm that creates and invests in companies developing therapeutics, diagnostics, genomics, gene therapy, RNA therapeutics and medical devices. The firm is led by founder Jeffrey (Jeff) Bird, MD, PhD, who draws on operational, commercialization and board experience to provide capital, board leadership and strategic support to founding teams.
Industries
Nr. of Employees
small (1-50)
Bluebird Ventures
C/O Sutter Hill Ventures, 755 Page Mill Road, Suite A200, Palo Alto CA 94304
Portfolio
Developing therapeutics that stimulate muscle growth and mitochondrial biogenesis; clinical data in degenerative muscle disease indications including Becker’s Muscular Dystrophy. Bluebird: Series A investor and board member.
#Mitochondrial biogenesis / muscle disease therapeutics
Developed an antibody against CD47; went public in 2018 and was acquired by Gilead in 2019/2020 for $4.9 billion. Bluebird: Series A investor and lead director.
#Immuno-Oncology
Gene therapy company focused on indications including diabetes and ophthalmologic diseases; noted for manufacturing capabilities. Bluebird: Series A investor.
#Gene therapy
Developing peptide-based cytokine activating drugs for cancer treatment. Bluebird: Series Seed investor.
#Cytokine-activating cancer drugs (peptide-based)
Developing a ‘GMP factory in a box’ for agile RNA drug development. Bluebird: Series A investor.
#RNA therapeutics / RNA manufacturing
Developing an implantable intravascular pump for congestive heart failure and associated renal disease; clinical studies planned to begin late 2020. Bluebird: Series D investor and board member.
#Medical device (heart failure)
Developing therapeutics that stimulate muscle growth and mitochondrial biogenesis; clinical data in degenerative muscle disease indications including Becker’s Muscular Dystrophy. Bluebird: Series A investor and board member.
#Mitochondrial biogenesis / muscle disease therapeutics
Developed an antibody against CD47; went public in 2018 and was acquired by Gilead in 2019/2020 for $4.9 billion. Bluebird: Series A investor and lead director.
#Immuno-Oncology
Gene therapy company focused on indications including diabetes and ophthalmologic diseases; noted for manufacturing capabilities. Bluebird: Series A investor.
#Gene therapy
Developing peptide-based cytokine activating drugs for cancer treatment. Bluebird: Series Seed investor.
#Cytokine-activating cancer drugs (peptide-based)
Developing a ‘GMP factory in a box’ for agile RNA drug development. Bluebird: Series A investor.
#RNA therapeutics / RNA manufacturing
Developing an implantable intravascular pump for congestive heart failure and associated renal disease; clinical studies planned to begin late 2020. Bluebird: Series D investor and board member.
#Medical device (heart failure)